ID   CWR-R1-AD1
AC   CVCL_ZC60
SY   R1-AD1
DR   cancercelllines; CVCL_ZC60
DR   Kerafast; EMN024-FP
DR   Wikidata; Q98125805
RX   PubMed=23117885;
RX   PubMed=24101480;
CC   Population: Caucasian.
CC   Characteristics: Clone of CWR-R1 that harbors one intact AR gene copy, express full-length AR and exhibit growth stimulation in response to androgens and growth suppression in response to AR antagonists, including enzalutamide (PubMed=24101480).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4833 ! CWR-R1
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=23117885; DOI=10.1158/0008-5472.CAN-12-3630;
RA   Li Y.-M., Chan S.-C., Brand L.J., Hwang T.H., Silverstein K.A.T.,
RA   Dehm S.M.;
RT   "Androgen receptor splice variants mediate enzalutamide resistance in
RT   castration-resistant prostate cancer cell lines.";
RL   Cancer Res. 73:483-489(2013).
//
RX   PubMed=24101480; DOI=10.1073/pnas.1308587110;
RA   Nyquist M.D., Li Y.-M., Hwang T.H., Manlove L.S., Vessella R.L.,
RA   Silverstein K.A.T., Voytas D.F., Dehm S.M.;
RT   "TALEN-engineered AR gene rearrangements reveal endocrine uncoupling
RT   of androgen receptor in prostate cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:17492-17497(2013).
//